(Q38076320)

28 August 2017

1 reference

title

Atypical antipsychotics and diabetic ketoacidosis: a review (English)

1 reference

28 August 2017

0 references

diabetic ketoacidosis

1 reference

4

Celine Teo

1 reference

28 August 2017

Melanie D Guenette

1

1 reference

28 August 2017

Margaret Hahn

series ordinal

2

1 reference

28 August 2017

Tony A Cohn

series ordinal

3

1 reference

28 August 2017

Gary J Remington

series ordinal

5

1 reference

28 August 2017

publication date

24 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

226

1 reference

28 August 2017

issue

1

1 reference

28 August 2017

page(s)

1-12

1 reference

Where to Position Clozapine: Re-Examining the Evidence

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetic ketoacidosis and clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Ten years of antipsychotic prescribing to children: a Canadian population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Annual Deaths Attributable to Obesity in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Atypical antipsychotic induced weight gain: pathophysiology and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Fatal olanzapine-induced hyperglycemic ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Euglycemic clamp study in clozapine-induced diabetic ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Pharmacological management of atypical antipsychotic-induced weight gain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

A UK audit of screening for the metabolic side effects of antipsychotics in community patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Substantial changes in prescription recommendations for bipolar disorder in Canada: 2002-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetic ketoacidosis associated with aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Atypical antipsychotics and new onset diabetes mellitus. An overview of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Management of treatment resistance in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Neuroleptic malignant syndrome and diabetic keto-acidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetic ketoacidosis induced by aripiprazole in a 12-year-old boy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetes associated with atypical antipsychotic treatment may be severe but reversible: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Prevalence and correlates of diabetes in national schizophrenia samples.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Association of olanzapine-induced weight gain with an increase in body fat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Hyperglycaemic crises and lactic acidosis in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Complete Resolution of Olanzapine-Induced Diabetic Ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Visceral and subcutaneous fat in patients treated with olanzapine: a case series

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Mechanisms and physiological significance of the cholinergic control of pancreatic beta-cell function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Patterns of antipsychotic medication use in Australia 2002-2007.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetic keto-acidotic (DKA) coma following olanzapine initiation in a previously euglycaemic woman and successful continued therapy with olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Increasing insulin dose for olanzapine-related diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetic ketoacidosis and elevated serum lipase in the setting of aripiprazole therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Hyperglycemic crises in adult patients with diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Olanzapine-associated diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Atypical antipsychotic drugs and hyperglycemia in adolescents

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Risperidone-associated diabetes mellitus: a pharmacovigilance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetic ketoacidosis and severe dyslipidemia in an adult psychotic man with olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Low-Dose Clozapine and Diabetic Ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Incidence of newly diagnosed diabetes attributable to atypical antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Second-generation antipsychotics for schizophrenia: can we resolve the conflict?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Effectiveness of antipsychotic drugs in patients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Risperidone-associated newly diagnosed diabetes and fatal diabetes ketoacidosis in a young schizophrenic patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetic ketoacidosis associated with aripiprazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Physical health monitoring of patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Central Nervous System Delivery of the Antipsychotic Olanzapine Induces Hepatic Insulin Resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Receptor occupancy-based analysis of the contributions of various receptors to antipsychotics-induced weight gain and diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Guideline concordant monitoring of metabolic risk in people treated with antipsychotic medication: systematic review and meta-analysis of screening practices.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Risperidone-associated transient diabetic ketoacidosis and diabetes mellitus type 1 in a patient treated with valproate and lithium

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Trends in antipsychotic prescribing practices in an urban community mental health clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Genetics of antipsychotic treatment emergent weight gain in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

The metabolic effects of antipsychotic medications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Simultaneous side effects of both clozapine and valproate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Olanzapine-induced diabetic ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Risk of diabetic ketoacidosis after exposure to risperidone or olanzapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Effects of olanzapine and ziprasidone on glucose tolerance in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

21 January 2018

From prison with coma

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

New-onset diabetic ketoacidosis in a schizophrenic patient with multiple autoimmune disease during treatment with risperidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Differential effects of various typical and atypical antipsychotics on plasma glucose and insulin levels in the mouse: evidence for the involvement of sympathetic regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Olanzapine-associated severe hyperglycemia, ketonuria, and acidosis: case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetic ketoacidosis associated with olanzapine in an adolescent patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Antipsychotic prescribing to older people living in care homes and the community in England and Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Research on adverse drug events. I. Muscarinic M3 receptor binding affinity could predict the risk of antipsychotics to induce type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

New-onset diabetic ketoacidosis associated with quetiapine: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Evaluation of insulin sensitivity in healthy volunteers treated with olanzapine, risperidone, or placebo: a prospective, randomized study using the two-step hyperinsulinemic, euglycemic clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Near fatal ketoacidosis with olanzapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Rapid onset of quetiapine-induced diabetic ketoacidosis in an elderly patient: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetic ketoacidosis in a patient treated with olanzapine, valproic acid, and venlafaxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Fatal olanzapine-induced ketoacidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Modulating effects of olanzapine on the development of diabetic ketoacidosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Clozapine-induced alteration of glucose homeostasis in the rat: the contribution of hypothalamic-pituitary-adrenal axis activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Diabetic ketoacidosis: risk factors and management strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Life-threatening hyperglycemia and acidosis related to olanzapine: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Orally disintegrating and oral standard olanzapine tablets similarly elevate the homeostasis model assessment of insulin resistance index and plasma triglyceride levels in 12 healthy men: a randomized crossover study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Effects of olanzapine and haloperidol on the metabolic status of healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

New-onset diabetes and ketoacidosis with atypical antipsychotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Rhabdomyolysis, pancreatitis, and hyperglycemia with ziprasidone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Ketoacidosis as a side-effect of clozapine: a case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00213-013-2982-3

Clozapine and diabetic ketoacidosis

21 January 2018

1 reference

12 December 2020

Diabetic ketoacidosis with olanzapine treatment

1 reference

12 December 2020

Atypical antipsychotics and glycemia: a case report

1 reference

12 December 2020

Pancreatitis and diabetic ketoacidosis with quetiapine use

1 reference

12 December 2020

Diabetic ketoacidosis

1 reference

12 December 2020

The Texas Medication Algorithm Project antipsychotic algorithm for schizophrenia: 2006 update.

1 reference

12 December 2020

Diabetic ketoacidosis with clozapine treatment

1 reference

12 December 2020

Managing weight gain and metabolic issues in patients treated with atypical antipsychotics.

1 reference

12 December 2020

Diabetic ketoacidosis, neuroleptic malignant syndrome, and myocardial infarction in a patient taking risperidone and lithium carbonate

1 reference

12 December 2020

Diabetic ketoacidosis associated with clozapine treatment

1 reference

12 December 2020

Cardiovascular risk reduction among African Americans: a call to action

1 reference

12 December 2020

Diabetic ketoacidosis associated with lithium: case report

1 reference

12 December 2020

Elevated hemoglobin A1c as a possible indicator of diabetes mellitus and diabetic ketoacidosis in schizophrenia patients receiving atypical antipsychotics.

1 reference

12 December 2020

Diabetic ketoacidosis associated with clozapine treatment

1 reference

12 December 2020

Adiposity and insulin sensitivity derived from intravenous glucose tolerance tests in antipsychotic-treated patients

1 reference

12 December 2020

A six-to-ten weeks' follow-up study on the effects of olanzapine on abdominal fat and other metabolic parameters in patients with psychoses--an imaging-based study with controls.

1 reference

12 December 2020

Acute pancreatitis and diabetic ketoacidosis in a schizophrenic patient taking olanzapine

1 reference

12 December 2020

Atypical antipsychotics and effects of muscarinic, serotonergic, dopaminergic and histaminergic receptor binding on insulin secretion in vivo: an animal model

1 reference

12 December 2020

Schizophrenia and diabetes mellitus

1 reference

12 December 2020

Off-label use of antipsychotic medications in Medicaid.

1 reference

12 December 2020

Novel antipsychotics: comparison of weight gain liabilities.

1 reference

12 December 2020

Clozapine monotherapy and ketoacidosis

1 reference

12 December 2020

Clozapine-induced diabetic ketoacidosis

1 reference

12 December 2020

A user' guide to clozapine

1 reference

12 December 2020

Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases

1 reference

12 December 2020

Diabetic ketoacidosis from clozapine and lithium cotreatment

1 reference

12 December 2020

Olanzapine-induced ketoacidosis with diabetes mellitus

1 reference

12 December 2020

New onset diabetes with ketoacidosis attributed to quetiapine

1 reference

12 December 2020

Acute effects of atypical antipsychotics on whole-body insulin resistance in rats: implications for adverse metabolic effects

1 reference

12 December 2020

A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus.

1 reference

12 December 2020

Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol

1 reference

12 December 2020

Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review

1 reference

12 December 2020

Antipsychotic-induced weight gain: a comprehensive research synthesis

1 reference

12 December 2020

Antipsychotic-induced weight gain: a review of the literature

1 reference

12 December 2020

Diabetes mellitus and schizophrenia: historical perspective

1 reference

12 December 2020

Acute administration of clozapine concurrently increases blood glucose and circulating plasma ghrelin levels in rats

1 reference

12 December 2020

Acute insulin response and beta-cell compensation in normal subjects treated with olanzapine or risperidone for 2 weeks.

1 reference

12 December 2020

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

1 reference

12 December 2020

Diabetes mellitus associated with atypical antipsychotic medications: new case report and review of the literature

1 reference

12 December 2020

Aripiprazole-induced agitation after clozapine discontinuation: a case report.

1 reference

12 December 2020

Olanzapine effects on body composition, food preference, glucose metabolism and insulin sensitivity in the rat

1 reference

12 December 2020

Diabetes as a result of atypical anti-psychotic drugs--a report of three cases

1 reference

12 December 2020

Novel antipsychotics and new onset diabetes

1 reference

12 December 2020

Elevated lipase and diabetic ketoacidosis associated with aripiprazole

1 reference

12 December 2020

New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment

1 reference

12 December 2020

New-onset diabetic ketoacidosis induced by the addition of perospirone hydrochloride in a patient treated with risperidone

1 reference

12 December 2020

Consensus development conference on antipsychotic drugs and obesity and diabetes

1 reference

12 December 2020

Diabetic ketoacidosis associated with risperidone treatment?

1 reference

12 December 2020

[Diabetes mellitus associated with atypical antipsychotic medications: case report and review of the literature]

1 reference

12 December 2020

Olanzapine-induced diabetic ketoacidosis in a Chinese man.

1 reference

12 December 2020

10.1007/S00213-013-2982-3

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

1051870213

0 references

1 reference